The PIM kinases in hematological cancers

Expert Review of Hematology

Volumn 5, Issue 1, 2012, Pages 81-96

  Alvarado, Yesid ^a   Giles, Francis J ^b   Swords, Ronan T ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

AKT; apoptosis; cell signaling; drug development; kinase; mTOR; PI3K; PIM kinase; PIM kinase inhibitor

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BENZOTHIENOPYRIMIDINONE; BISINDOLYLMALEIMIDE; CENTAUREIDIN; CX 6258; CXR 1002; ETP 39010; GNE 652; M 110; ONCOPROTEIN; PERFLUOROOCTANOIC ACID; PROTEIN KINASE PIM 1; RAPAMYCIN; SGI 1776; SMI 4A; STAUROSPORINE; THIAZOLIDINE DERIVATIVE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE 1; PROTEIN SERINE THREONINE KINASE 2; PROTEIN SERINE THREONINE KINASE 3; PROTEIN SERINE THREONINE KINASE INHIBITOR; SMI 4 A; STAT PROTEIN; STROMAL CELL DERIVED FACTOR 1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE REGULATION; CELL METABOLISM; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DIARRHEA; DOWNSTREAM PROCESSING; DRUG MEGADOSE; FATIGUE; FOLLICULAR LYMPHOMA; GENE; HEMATOLOGIC MALIGNANCY; HINGE REGION; HUMAN; HYPERTRANSAMINASEMIA; IN VITRO STUDY; IN VIVO CULTURE; KAPOSI SARCOMA; KIDNEY FAILURE; LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MYELOPROLIFERATIVE DISORDER; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PIM1 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SINGLE DRUG DOSE; VIRUS INFECTION; VOMITING; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 6; ENZYME REGULATION; GENETIC TRANSCRIPTION; IN VIVO STUDY; NAUSEA AND VOMITING; PROTEIN SERINE THREONINE KINASE 1 GENE; PROTEIN SERINE THREONINE KINASE 2 GENE; PROTEIN SERINE THREONINE KINASE 3 GENE; PROTEIN TARGETING; PROTO ONCOGENE; RNA TRANSLATION; SIGNAL TRANSDUCTION;

ANIMALS; HEMATOLOGIC NEOPLASMS; HUMANS; PROTO-ONCOGENE PROTEINS C-PIM-1;

EID: 84856249992     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.69     Document Type: Review

References (176)

1. Bachmann M, Moroy T. The serine/ threonine kinase PIM-1. Int. J. Biochem. Cell Biol. 37(4), 726-730 (2005).
2. Cuypers HT, Selten G, Quint W et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37(1), 141-150 (1984). (Pubitemid 14079845)
3. Meeker TC, Nagarajan L, Ar-Rushdi A, Rovera G, Huebner K, Croce CM. Characterization of the human PIM-1 gene: a putative proto-oncogene coding for a tissue specific member of the protein kinase family. Oncogene Res. 1(1), 87-101 (1987). (Pubitemid 18041730)
4. Breuer ML, Cuypers HT, Berns A. Evidence for the involvement of PIM-2, a new common proviral insertion site, in progression of lymphomas. EMBO J. 8(3), 743-748 (1989).
5. Feldman JD, Vician L, Crispino M et al. KID-1, a protein kinase induced by depolarization in brain. J. Biol. Chem. 273(26), 16535-16543 (1998). (Pubitemid 28311439)
6. Mikkers H, Allen J, Knipscheer P et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat. Gen. 32(1), 153-159 (2002). (Pubitemid 34977211)
7. Van Lohuizen M, Verbeek S, Krimpenfort P et al. Predisposition to lymphomagenesis in PIM-1 transgenic mice: cooperation with c-MYC and N-MYC in murine leukemia virus-induced tumors. Cell 56(4), 673-682 (1989). (Pubitemid 19065532)
8. Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a BCL-2-dependent pathway. Oncogene 18(27), 4022-4031 (1999). (Pubitemid 29361341)
9. Pircher TJ, Zhao S, Geiger JN, Joneja B, Wojchowski DM. PIM-1 kinase protects hematopoietic FDC cells from genotoxin-induced death. Oncogene 19(32), 3684-3692 (2000). (Pubitemid 30608490)
10. Berns A, Breuer M, Verbeek S, Van Lohuizen M. Transgenic mice as a means to study synergism between oncogenes. Int. J. Cancer Suppl. 4, 22-25 (1989). (Pubitemid 19283169)
11. Pasqualucci L, Neumeister P, Goossens T et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412(6844), 341-346 (2001). (Pubitemid 32691848)
12. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849), 822-826 (2001). (Pubitemid 32801464)
13. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33PIM is expressed during fetal hematopoiesis and in diverse leukemias. Proc. Natl Acad. Sci. USA 86(22), 8857-8861 (1989). (Pubitemid 20010324)
14. Mizuki M, Schwable J, Steur C et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific FLT3 mutations. Blood 101(8), 3164-3173 (2003). (Pubitemid 36858011)
15. Tamburini J, Green AS, Bardet V et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114(8), 1618-1627 (2009).
16. Woodland RT, Fox CJ, Schmidt MR et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 111(2), 750-760 (2008).
17. Cohen AM, Grinblat B, Bessler H et al. Increased expression of the hPIM-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk. Lymphoma 45(5), 951-955 (2004). (Pubitemid 38444671)
18. Huttmann A, Klein-Hitpass L, Thomale J et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia 20(10), 1774-1782 (2006). (Pubitemid 44574989)
19. Ayala GE, Dai H, Ittmann M et al. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 64(17), 6082-6090 (2004). (Pubitemid 39129408)
20. Deneen B, Welford SM, Ho T, Hernandez F, Kurland I, Denny CT. PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ ETS oncoproteins. Mol. Cell Biol. 23(11), 3897-3908 (2003). (Pubitemid 36597468)
21. Fujii C, Nakamoto Y, Lu P et al. Aberrant expression of serine/threonine kinase PIM-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int. J. Cancer 114(2), 209-218 (2005). (Pubitemid 40194286)
22. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. PIM-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block BAD-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res. 66(13), 6741-6747 (2006). (Pubitemid 44085632)
23. Zheng HC, Tsuneyama K, Takahashi H et al. Aberrant PIM-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J. Cancer Res. Clin. Oncol. 134(4), 481-488 (2008). (Pubitemid 351322384)
24. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of PIM oncogenes in tumorigenesis. Nat. Rev. 11(1), 23-34 (2011).
25. Zhu N, Ramirez LM, Lee RL, Magnuson NS, Bishop GA, Gold MR. CD40 signaling in B cells regulates the expression of the PIM-1 kinase via the NF-kappa B pathway. J Immunol. 168(2), 744-754 (2002). (Pubitemid 34049575)
26. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase PIM-2 is a transcriptionally regulated apoptotic inhibitor. Genes Develop. 17(15), 1841-1854 (2003). (Pubitemid 36944562)
27. Saris CJ, Domen J, Berns A. The PIM-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J. 10(3), 655-664 (1991). (Pubitemid 21905520)
28. Ragoussis J, Senger G, Mockridge I et al. A testis-expressed Zn finger gene (ZNF76) in human 6p21.3 centromeric to the MHC is closely linked to the human homolog of the t-complex gene tcp-11. Genomics 14(3), 673-679 (1992).
29. Qian KC, Wang L, Hickey ER et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human PIM-1 kinase. J. Biol. Chem. 280(7), 6130-6137 (2005). (Pubitemid 40280098)
30. Aksoy I, Sakabedoyan C, Bourillot PY et al. Self-renewal of murine embryonic stem cells is supported by the serine/ threonine kinases PIM-1 and PIM-3. Stem Cells 25(12), 2996-3004 (2007). (Pubitemid 350294424)
31. Mikkers H, Nawijn M, Allen J et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol. Cell Biol. 24(13), 6104-6115 (2004). (Pubitemid 38787993)
32. Domen J, Van Der Lugt NM, Laird PW et al. Impaired interleukin-3 response in PIM-1-deficient bone marrow-derived mast cells. Blood 82(5), 1445-1452 (1993). (Pubitemid 23263960)
33. Katakami N, Kaneto H, Hao H et al. Role of PIM-1 in smooth muscle cell proliferation. J. Biol. Chem. 279(52), 54742-54749 (2004). (Pubitemid 40053219)
34. Muraski JA, Rota M, Misao Y et al. PIM-1 regulates cardiomyocyte survival downstream of AKT. Nat. Med. 13(12), 1467-1475 (2007). (Pubitemid 350224243)
35. Zippo A, De Robertis A, Bardelli M, Galvagni F, Oliviero S. Identification of FLK-1 target genes in vasculogenesis: PIM-1 is required for endothelial and mural cell differentiation in vitro. Blood 103(12), 4536-4544 (2004). (Pubitemid 38745981)
36. Gapter LA, Magnuson NS, Ng KY, Hosick HL. PIM-1 kinase expression during murine mammary development. Biochem. Biophys. Res. Commun. 345(3), 989-997 (2006). (Pubitemid 43776503)
37. Amaravadi R, Thompson CB. The survival kinases AKT and PIM as potential pharmacological targets. J. Clin. Investig. 115(10), 2618-2624 (2005). (Pubitemid 41434384)
38. Wang Z, Bhattacharya N, Weaver M et al. PIM-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J. Vet. Sci. 2(3), 167-179 (2001).
39. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-a activates multiple STAT proteins and upregulates proliferation-associated IL-2Ra, c-MYC, and PIM-1 genes in human T cells. Blood 93(6), 1980-1991 (1999). (Pubitemid 29128500)
40. Wierenga AT, Vellenga E, Schuringa JJ. Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels. Mol. Cell. Biol. 28(21), 6668-6680 (2008).
41. Li J, Peet GW, Balzarano D et al. Novel NEMO/IkB kinase and NF-kB target genes at the pre-B to immature B cell transition. J. Biol. Chem. 276(21), 18579-18590 (2001).
42. Chen J, Kobayashi M, Darmanin S et al. Hypoxia-mediated up-regulation of PIM-1 contributes to solid tumor formation. Am. J. Pathol. 175(1), 400-411 (2009).
43. Zhao Y, Hamza MS, Leong HS et al. Kruppel-like factor 5 modulates p53- independent apoptosis through PIM1 survival kinase in cancer cells. Oncogene 27(1), 1-8 (2008).
44. Yip-Schneider MT, Horie M, Broxmeyer HE. Transcriptional induction of PIM-1 protein kinase gene expression by interferon g and posttranscriptional effects on costimulation with steel factor. Blood 85(12), 3494-3502 (1995).
45. Losman J, Chen XP, Jiang H et al. IL-4 signaling is regulated through the recruitment of phosphatases, kinases, and SOCS proteins to the receptor complex. Cold Spring Harb. Symp. Quant. Biol. 64, 405-416 (1999). (Pubitemid 30329305)
46. Chen XP, Losman JA, Cowan S et al. PIM serine/threonine kinases regulate the stability of SOCS-1 protein. Proc. Natl Acad. Sci. USA 99(4), 2175-2180 (2002). (Pubitemid 34169034)
47. Peltola KJ, Paukku K, Aho TL, Ruuska M, Silvennoinen O, Koskinen PJ. PIM-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 103(10), 3744-3750 (2004). (Pubitemid 38596290)
48. Hoover DS, Wingett DG, Zhang J, Reeves R, Magnuson NS. PIM-1 protein expression is regulated by its 5'-untranslated region and translation initiation factor elF-4E. Cell Growth Differ. 8(12), 1371-1380 (1997). (Pubitemid 28008733)
49. Hoover D, Friedmann M, Reeves R, Magnuson NS. Recombinant human PIM-1 protein exhibits serine/threonine kinase activity. J. Biol. Chem. 266(21), 14018-14023 (1991). (Pubitemid 21907455)
50. Friedmann M, Nissen MS, Hoover DS, Reeves R, Magnuson NS. Characterization of the proto-oncogene PIM-1: kinase activity and substrate recognition sequence. Arch. Biochem. Biophys. 298(2), 594-601 (1992).
51. Palaty CK, Clark-Lewis I, Leung D, Pelech SL. Phosphorylation site substrate specificity determinants for the PIM-1 protooncogene-encoded protein kinase. Biochem. Cell Biol. Biochim. Biol. Cell. 75(2), 153-162 (1997). (Pubitemid 127733139)
52. Bullock AN, Debreczeni J, Amos AL, Knapp S, Turk BE. Structure and substrate specificity of the PIM-1 kinase. J. Biol. Chem. 280(50), 41675-41682 (2005). (Pubitemid 43000572)
53. Palaty CK, Kalmar G, Tai G et al. Identification of the autophosphorylation sites of the Xenopus laevis PIM-1 proto-oncogene-encoded protein kinase. J. Biol. Chem. 272(16), 10514-10521 (1997). (Pubitemid 27181056)
54. Shay KP, Wang Z, Xing PX, Mckenzie IF, Magnuson NS. PIM-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol. Cancer Res. 3(3), 170-181 (2005). (Pubitemid 40524900)
55. Mizuno K, Shirogane T, Shinohara A, Iwamatsu A, Hibi M, Hirano T. Regulation of PIM-1 by Hsp90. Biochem. Biophys. Res. Commun. 281(3), 663-669 (2001). (Pubitemid 32917852)
56. Nasser MW, Datta J, Nuovo G et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J. Biol. Chem. 283(48), 33394-33405 (2008).
57. Huang X, Ding L, Bennewith KL et al. Hypoxia-inducible MIR-210 regulates normoxic gene expression involved in tumor initiation. Mol. Cell 35(6), 856-867 (2009).
58. Losman JA, Chen XP, Vuong BQ, Fay S, Rothman PB. Protein phosphatase 2A regulates the stability of PIM protein kinases. J. Biol. Chem. 278(7), 4800-4805 (2003). (Pubitemid 36800983)
59. Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS. Negative regulation of PIM-1 protein kinase levels by the B56beta subunit of PP2A. Oncogene 26(35), 5145-5153 (2007). (Pubitemid 47206954)
60. Laird PW, Van Der Lugt NM, Clarke A et al. In vivo analysis of PIM-1 deficiency. Nucleic Acids Res. 21(20), 4750-4755 (1993). (Pubitemid 23312750)
61. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by PIM-1 kinase. Biochim. Biophys. Acta 1593(1), 45-55 (2002). (Pubitemid 35335911)
62. Leverson JD, Koskinen PJ, Orrico FC et al. PIM-1 kinase and p100 cooperate to enhance c-Myb activity. Mol. Cell 2(4), 417-425 (1998). (Pubitemid 128381294)
63. Bhattacharya N, Wang Z, Davitt C, Mckenzie IF, Xing PX, Magnuson NS. PIM-1 associates with protein complexes necessary for mitosis. Chromosoma 111(2), 80-95 (2002). (Pubitemid 36067383)
64. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. PIM kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 68(13), 5076-5085 (2008).
65. Bachmann M, Hennemann H, Xing PX, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase PIM-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for PIM-1 at the G2/M cell cycle checkpoint. J. Biol. Chem. 279(46), 48319-48328 (2004). (Pubitemid 39540988)
66. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between PIM-1 kinase and Cdc25A phosphatase. Implications for the PIM-1-mediated activation of the c-MYC signaling pathway. J. Biol. Chem. 274(26), 18659-18666 (1999).
67. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for PIM-1 and c-MYC in STAT3- mediated cell cycle progression and antiapoptosis. Immunity 11(6), 709-719 (1999). (Pubitemid 30030710)
68. Eilers M, Eisenman RN. MYC's broad reach. Genes Dev. 22(20), 2755-2766 (2008).
69. Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat. Cell Biol. 9(8), 932-944 (2007). (Pubitemid 47190448)
70. Zhang Y, Wang Z, Li X, Magnuson NS. PIM kinase-dependent inhibition of c-MYC degradation. Oncogene 27(35), 4809-4819 (2008).
71. Zippo A, Serafini R, Rocchigiani M, Pennacchini S, Krepelova A, Oliviero S. Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell 138(6), 1122-1136 (2009).
72. Wang J, Kim J, Roh M et al. PIM1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 29(17), 2477-2487 (2010).
73. Rainio EM, Sandholm J, Koskinen PJ. Cutting edge: transcriptional activity of NFATc1 is enhanced by the PIM-1 kinase. J. Immunol. 168(4), 1524-1527 (2002). (Pubitemid 34135742)
74. Koike N, Maita H, Taira T, Ariga H, Iguchi-Ariga SM. Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by PIM-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1). FEBS Lett. 467(1), 17-21 (2000). (Pubitemid 30069534)
75. Maita H, Harada Y, Nagakubo D et al. PAP-1, a novel target protein of phosphorylation by PIM-1 kinase. Eur. J. Biochem. FEBS 267(16), 5168-5178 (2000). (Pubitemid 30641313)
76. Ishibashi Y, Maita H, Yano M et al. PIM-1 translocates sorting nexin 6/TRAF4- associated factor 2 from cytoplasm to nucleus. FEBS Lett. 506(1), 33-38 (2001). (Pubitemid 32925227)
77. Didichenko SA, Spiegl N, Brunner T, Dahinden CA. IL-3 induces a PIM1- dependent antiapoptotic pathway in primary human basophils. Blood 112(10), 3949-3958 (2008).
78. Danial NN. BAD: undertaker by night, candyman by day. Oncogene 27(Suppl. 1), S53-S70 (2008).
79. Yan B, Zemskova M, Holder S et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J. Biol. Chem. 278(46), 45358-45367 (2003). (Pubitemid 37432672)
80. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. PIM-1 kinase promotes inactivation of the pro-apoptotic BAD protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 571(1-3), 43-49 (2004). (Pubitemid 38992921)
81. Macdonald A, Campbell DG, Toth R, Mclauchlan H, Hastie CJ, Arthur JS. PIM kinases phosphorylate multiple sites on BAD and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol. 7, 1 (2006).
82. Datta SR, Dudek H, Tao X et al. AKT phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2), 231-241 (1997). (Pubitemid 27456390)
83. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87(4), 619-628 (1996). (Pubitemid 26386936)
84. Danial NN, Gramm CF, Scorrano L et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424(6951), 952-956 (2003). (Pubitemid 37051687)
85. Zhang F, Beharry ZM, Harris TE et al. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol. Ther. 8(9), 846-853 (2009).
86. Gu JJ, Wang Z, Reeves R, Magnuson NS. PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. Oncogene 28(48), 4261-4271 (2009).
87. Hammerman PS, Fox CJ, Cinalli RM et al. Lymphocyte transformation by PIM-2 is dependent on nuclear factor-kB activation. Cancer Res. 64(22), 8341-8348 (2004). (Pubitemid 39491773)
88. Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. PIM and AKT oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 105(11), 4477-4483 (2005). (Pubitemid 40720797)
89. Kane LP, Mollenauer MN, Xu Z, Turck CW, Weiss A. AKT-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription. Mol. Cell Biol. 22(16), 5962-5974 (2002). (Pubitemid 34815843)
90. Mcgowan KA, Li JZ, Park CY et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat. Genet. 40(8), 963-970 (2008).
91. Hogan C, Hutchison C, Marcar L et al. Elevated levels of oncogenic protein kinase PIM-1 induce the p53 pathway in cultured cells and correlate with increased MDM in mantle cell lymphoma. J. Biol. Chem. 283(26), 18012-18023 (2008).
92. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol. 36(Suppl. 3), S3-S17 (2009).
93. Laplante M, Sabatini DM. mTOR signaling at a glance. J. Cell Sci. 122(Pt 20), 3589-3594 (2009).
94. Fox CJ, Hammerman PS, Thompson CB. The PIM kinases control rapamycin-resistant T cell survival and activation. J. Exp. Med. 201(2), 259-266 (2005). (Pubitemid 40189435)
95. Schatz JH, Wendel HG. Oncogenic PIM kinase activity provides resistance to MTOR inhibition in vitro and in vivo. ASH Annual Meeting Abstracts 114(22), 3974 (2009).
96. Beharry Z, Mahajan S, Zemskova M et al. The PIM protein kinases regulate energy metabolism and cell growth. Proc. Natl Acad. Sci. USA 108(2), 528-533 (2011).
97. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5(3), 219-234 (2006). (Pubitemid 43336035)
98. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr. Opin. Cell Biol. 19(2), 223-229 (2007). (Pubitemid 46386401)
99. Niu G, Briggs J, Deng J et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1a RNA expression in both tumor cells and tumor-associated myeloid cells. Mol. Cancer Res. 6(7), 1099-1105 (2008).
100. Horiguchi A, Asano T, Kuroda K et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br. J. Cancer 102(11), 1592-1599 (2010).
101. Liu M, Li D, Aneja R et al. PO(2)- dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway. J. Biol. Chem. 282(24), 17581-17586 (2007). (Pubitemid 47100273)
102. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat. 14(3), 191-201 (2011).
103. Chen J, Kobayashi M, Darmanin S et al. PIM-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene 28(28), 2581-2592 (2009).
104. Xie YN, Burcu M, Baer MR. PKC412 directly inhibits the serine/threonine protein kinase PIM-1 in cell lines and acute myeloid leukemia cells as a novel mechanism of inhibition of multidrug resistance. ASH Annual Meeting Abstracts 112(11), 2655 (2008).
105. Chen W, Kumar AR, Hudson WA et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 13(5), 432-440 (2008). (Pubitemid 351609442)
106. Kim KT, Baird K, Ahn JY et al. PIM-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105(4), 1759-1767 (2005). (Pubitemid 40223700)
107. Agrawal S, Koschmieder S, Baumer N et al. PIM2 complements FLT3 wild-type receptor in hematopoietic progenitor cell transformation. Leukemia 22(1), 78-86 (2008).
108. Hu YL, Passegue E, Fong S, Largman C, Lawrence HJ. Evidence that the PIM1 kinase gene is a direct target of HOXA9. Blood 109(11), 4732-4738 (2007). (Pubitemid 46827765)
109. Hsi ED, Jung SH, Lai R et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a cancer and leukemia group B 59909 correlative science study. Leuk. Lymphoma 49(11), 2081-2090 (2008).
110. Poulsen CB, Borup R, Nielsen FC et al. Microarray-based classification of diffuse large B-cell lymphoma. Eur. J. Haematol. 74(6), 453-465 (2005). (Pubitemid 40695044)
111. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 100(17), 9991-9996 (2003). (Pubitemid 37087056)
112. Grundler R, Brault L, Gasser C et al. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J. Exp. Med. 206(9), 1957-1970 (2009).
113. Spoo AC, Lubbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 109(2), 786-791 (2007). (Pubitemid 46105982)
114. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood 106(6), 1901-1910 (2005). (Pubitemid 41291700)
115. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim. Biophys. Acta 1768(4), 952-963 (2007). (Pubitemid 46452548)
116. Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase PIM-1 in the BCR/ABL-mediated leukemogenesis. Blood 99(12), 4531-4539 (2002). (Pubitemid 34627224)
117. Adam M, Pogacic V, Bendit M et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res. 66(7), 3828-3835 (2006).
118. Wernig G, Gonneville JR, Crowley BJ et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the MYC and PIM proto-oncogenes. Blood 111(7), 3751-3759 (2008).
119. Chen JL, Limnander A, Rothman PB. PIM-1 and PIM-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 111(3), 1677-1685 (2008). (Pubitemid 351213459)
120. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine/ threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95(6), 1004-1015 (2010).
121. Gaidano G, Pasqualucci L, Capello D et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood 102(5), 1833-1841 (2003). (Pubitemid 37022580)
122. Kumar A, Mandiyan V, Suzuki Y et al. Crystal structures of proto-oncogene kinase PIM1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J. Mol. Biol. 348(1), 183-193 (2005). (Pubitemid 40461849)
123. Kim J, Roh M, Abdulkadir S. Kinase-independent tumorigenicity of PIM1 oncogene. AACR Meeting Abstracts 2008, 3469 (2008).
124. Rainio EM, Ahlfors H, Carter KL et al. PIM kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity. Virology 333(2), 201-206 (2005). (Pubitemid 40250105)
125. Bajaj BG, Verma SC, Lan K, Cotter MA, Woodman ZL, Robertson ES. KSHV encoded LANA upregulates PIM-1 and is a substrate for its kinase activity. Virology 351(1), 18-28 (2006). (Pubitemid 44041082)
126. Cheng F, Weidner-Glunde M, Varjosalo M et al. KSHV reactivation from latency requires PIM-1 and PIM-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathogens 5(3), e1000324 (2009).
127. Jacobs MD, Black J, Futer O et al. PIM-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J. Biol. Chem. 280(14), 13728-13734 (2005). (Pubitemid 40517268)
128. Pogacic V, Bullock AN, Fedorov O et al. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res. 67(14), 6916-6924 (2007). (Pubitemid 47105539)
129. Isaac M, Siu A, Jongstra J. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms. Drug Resist. Updat. 14(4-5), 203-211 (2011).
130. Bullock AN, Russo S, Amos A et al. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. PloS One 4(10), e7112 (2009).
131. Holder S, Zemskova M, Zhang C et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol. Cancer Ther. 6(1), 163-172 (2007). (Pubitemid 46206679)
132. Cheney IW, Yan S, Appleby T et al. Identification and structure-activity relationships of substituted pyridones as inhibitors of PIM-1 kinase. Bioorgan. Med. Chem. Lett.17(6), 1679-1683 (2007). (Pubitemid 46274341)
133. Bullock AN, Debreczeni JE, Fedorov OY, Nelson A, Marsden BD, Knapp S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in Moloney murine leukemia virus (PIM-1) kinase. J. Med. Chem. 48(24), 7604-7614 (2005). (Pubitemid 41698801)
134. Lin Y, Song JH, Zhang Z et al. Novel small molecule PIM protein kinase inhibitors induce cell cycle arrest and apoptosis in human leukemias: a potential therapeutic approach. ASH Annual Meeting Abstracts 112(11), 1632 (2008).
135. Holder S, Lilly M, Brown ML. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorgan. Med. Chem. 15(19), 6463-6473 (2007). (Pubitemid 47212729)
136. Fedorov O, Marsden B, Pogacic V et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl Acad. Sci. USA 104(51), 20523-20528 (2007).
137. Debreczeni JE, Bullock AN, Atilla GE et al. Ruthenium half-sandwich complexes bound to protein kinase PIM-1. Angew. Chem. (Int. Ed.) 45(10), 1580-1585 (2006). (Pubitemid 44109229)
138. Bregman H, Meggers E. Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety. Org. Lett. 8(24), 5465-5468 (2006).
139. Grey R, Pierce AC, Bemis GW et al. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of PIM-1 kinase. Bioorgan. Med. Chem. Lett. 19(11), 3019-3022 (2009).
140. Gourley E, Liu XH, Lamb J et al. A potent small molecule PIM kinase inhibitor with activity in cell lines from hematological and solid malignancies. AACR Meeting Abstracts 2008, 4974 (2008).
141. Barnett AL, Ding S, Murray C et al. Anti-tumor activity of CXR1002, a novel anti-cancer compound that induces ER stress: human tumor xenograft efficacy and in vitro mode of action. Program and Abstracts of the AACR Meeting (2010) (Abstract 3566).
142. Tong Y, Stewart KD, Thomas S et al. Isoxazolo[3,4-b]quinoline-3,4(1H,9H)- diones as unique, potent and selective inhibitors for PIM-1 and PIM-2 kinases: chemistry, biological activities, and molecular modeling. Bioorgan. Med. Chem. Lett. 18(19), 5206-5208 (2008).
143. Qian K, Wang L, Cywin CL et al. Hit to lead account of the discovery of a new class of inhibitors of PIM kinases and crystallographic studies revealing an unusual kinase binding mode. J. Med. Chem. 52(7), 1814-1827 (2009).
144. Cozza G, Mazzorana M, Papinutto E et al. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem. J. 421(3), 387-395 (2009).
145. Pagano MA, Bain J, Kazimierczuk Z et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem. J. 415(3), 353-365 (2008).
146. Miduturu CV, Deng X, Kwiatkowski N et al. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem. Biol. 18(7), 868-879 (2011).
147. Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. PIM kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 114(19), 4150-4157 (2009).
148. Mumenthaler SM, Ng PY, Hodge A et al. Pharmacologic inhibition of PIM kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol. Cancer Ther. 8(10), 2882-2893 (2009).
149. Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. Mechanisms of cytotoxicity to PIM kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 118(3), 693-702 (2011).
150. Kelly KR, Espitia CM, Taverna P et al. Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br. J. Haematol. 156(1), 129-132 (2012).
151. Natarajan K, Burcu M, Baer MR. Inhibition of the serine/threonine kinase PIM-1 has anti-proliferative effects in acute myeloid leukemia (AML) and sensitizes multidrug resistant cells to chemotherapy. ASH Annual Meeting Abstracts 116(21), 1832 (2010).
152. Herreros B, Bischoff JR, Rodriguez ME et al. Pharmacological inhibition of PIM kinases in chronic lymphocytic leukemia cases with unfavorable prognosis markers. ASH Annual Meeting Abstracts 116(21), 2468 (2010).
153. Lin YW, Beharry ZM, Hill EG et al. A small molecule inhibitor of PIM protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 115(4), 824-833 (2010).
154. Lin Y, Graham AM, Costa LJ et al. Dual inhibition of mTOR and PIM kinase pathways using small molecule inhibitors synergistically kills myeloid leukemic cells in vitro and in vivo. ASH Annual Meeting Abstracts 116(21), 293 (2010).
155. Ebens AJ, Berry L, Chen YH et al. A selective PIM kinase inhibitor is highly active in multiple myeloma: the biology of single agent and PI3K/AKT/mTOR combination activity. ASH Annual Meeting Abstracts 116(21), 3001 (2010).
156. Munugalavadla V, Berry L, Chen YH et al. A selective PIM kinase inhibitor is highly active in multiple myeloma: mechanism of action and signal transduction studies. ASH Annual Meeting Abstracts 116(21), 4084 (2010).
157. O'Brien S, Haddach M, Borsan C et al. Discovery of selective small molecule pan-PIM kinase inhibitors with potent oral efficacy in murine xenograft models. ASH Annual Meeting Abstracts 114(22), 1726 (2009).
158. Chang M, Kanwar N, Feng E et al. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation. Mol. Cancer Ther. 9(9), 2478-2487 (2010).
159. Tao ZF, Hasvold LA, Leverson JD et al. Discovery of 3H-benzo[4,5] thieno[3,2-d] pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in Moloney murine leukemia virus (PIM) kinases. J. Med. Chem. 52(21), 6621-6636 (2009).
160. Macpherson IR, Bissett D, Petty RD et al. A first-in-human Phase 1 clinical trial of CXR1002 in patients (pts) with advanced cancer. ASCO Meeting Abstracts 29(Suppl. 15), 3063 (2011).
161. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. 9(8), 550-562 (2009).
162. Franke TF, Yang SI, Chan TO et al. The protein kinase encoded by the AKT proto-oncogene is a target of the PDGF- activated phosphatidylinositol 3-kinase. Cell 81(5), 727-736 (1995).
163. Marte BM, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J. R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr. Biol. 7(1), 63-70 (1997). (Pubitemid 27058941)
164. Skorski T, Bellacosa A, Nieborowska- Skorska M et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/AKT-dependent pathway. EMBO J. 16(20), 6151-6161 (1997). (Pubitemid 27458335)
165. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Invest. Drugs 3(2), 295-304 (2002). (Pubitemid 34456089)
166. Giles FJ. A PIM kinase inhibitor, please. Blood 105(11), 4158-4159 (2005).
167. Edinger AL, Thompson CB. AKT maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13(7), 2276-2288 (2002). (Pubitemid 34831333)
168. Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase 2 study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22(5), 909-918 (2004). (Pubitemid 41103603)
169. Gao N, Zhang Z, Jiang BH, Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun. 310(4), 1124-1132 (2003). (Pubitemid 37237653)
170. Mohi MG, Boulton C, Gu TL et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl Acad. Sci. USA 101(9), 3130-3135 (2004). (Pubitemid 38327746)
171. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100(4), 657-666 (2004). (Pubitemid 38176841)
172. Schatz JH, Oricchio E, Wolfe AL et al. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J. Exp. Med. 208(9), 1799-1807 (2011).
173. Akagi T, Shih LY, Ogawa S et al. Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells. Haematologica 94(9), 1301-1306 (2009).
174. Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX. PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing AKT phosphorylation, and activating apoptosis. J. Clin. Invest. 119(2), 362-375 (2009).
175. Li J, Hu XF, Loveland BE, Xing PX. PIM-1 expression and monoclonal antibody targeting in human leukemia cell lines. Exp. Hematol. 37(11), 1284-1294 (2009).
176. Olivotto M, Dello Sbarba P. Environmental restrictions within tumor ecosystems select for a convergent, hypoxia-resistant phenotype of cancer stem cells. Cell Cycle 7(2), 176-187 (2008). (Pubitemid 351366517)